Skip to main content
NewslettersWatchlist

Bausch Lomb Corporation(BLCO-T)
TSX

Today's Change
Real-Time Last Update
Day Low19.40
Day High19.85
Open:19.57
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Bausch Lomb Corporation up on Wednesday (BLCO)
AI-generated - The Globe and Mail
Bausch & Lomb: Top 10 Undervalued Growth Stocks on TSX (BLCO)
Baystreet
Stocks in play: Bausch + Lomb Corporation
The Globe and Mail
Thursday’s analyst upgrades and downgrades
Baystreet
Stocks in play: Bausch + Lomb Corporation
The Globe and Mail
Friday’s analyst upgrades and downgrades
The Globe and Mail
Why this bargain-hunting money manager is buying Fairfax India and Tim Hortons in China
AI-generated - The Globe and Mail
Bausch & Lomb: Top 10 Undervalued Growth Stocks on TSX (BLCO)
The Globe and Mail
Tuesday’s analyst upgrades and downgrades
AI-generated - The Globe and Mail
Bausch & Lomb: Top 10 Undervalued Growth Stocks on TSX (BLCO)
Baystreet
Stocks in play: Bausch + Lomb Corporation
The Globe and Mail
Monday’s analyst upgrades and downgrades
The Globe and Mail
Friday’s analyst upgrades and downgrades
ACCESSWIRE
Bausch Health's Bausch + Lomb Announces Completion of the Acquisition of XIIDRA(R)
Baystreet
Stocks in play: Bausch + Lomb Corporation
Baystreet
Stocks in play: Bausch + Lomb Corporation
Baystreet
Stocks in play: Bausch + Lomb Corporation
ACCESSWIRE
Bausch Health's Bausch + Lomb Announces Launch of Proposed Financing for Acquisition of XIIDRA(R)
Baystreet
Stocks in play: Bausch + Lomb Corporation
The Globe and Mail
Thursday’s analyst upgrades and downgrades
The Globe and Mail
Market movers: Stocks seeing action on Wednesday - and why
The Globe and Mail
Monday’s analyst upgrades and downgrades
ACCESSWIRE
Bausch Health’s Bausch + Lomb to Acquire Novartis’ XIIDRA(R)
Baystreet
Stocks in play: Bausch + Lomb Corporation
Baystreet
Stocks in play: Bausch + Lomb Corporation
The Globe and Mail
Bausch & Lomb: Stocks Analysts Recently Downgraded on TSX (BLCO)
Business Wire
Bausch + Lomb Announces First-Quarter 2023 Results and Provides 2023 Guidance
Business Wire
Bausch + Lomb Releases Annual Environmental, Social and Governance Report
Business Wire
Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting
Business Wire
Bausch + Lomb Announces 2023 Annual Meeting of Shareholder Results
Business Wire
Bausch + Lomb Announces U.S. Launch of StableVisc™ Cohesive Ophthalmic Viscosurgical Device and TotalVisc™ Viscoelastic System
Business Wire
Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting

Profile

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.